Short Proline-Rich Lipopeptide Potentiates Minocycline and Rifampin Against Multidrug- and Extensively Drug-Resistant Pseudomonas Aeruginosa

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2018 Feb 14

PMID 29437631

Citations 7

Authors

Ronald Domalaon

Yaroslav Sanchak

Linet Cherono Koskei

Yinfeng Lyu

George G Zhanel

Gilbert Arthur

Frank Schweizer

Affiliations

Soon will be listed here.

Abstract

A series of 16 short proline-rich lipopeptides (SPRLPs) were constructed to mimic longer naturally existing proline-rich antimicrobial peptides. Antibacterial assessment revealed that lipopeptides containing hexadecanoic acid (C) possess optimal antibacterial activity relative to others with shorter lipid components. SPRLPs were further evaluated for their potential to serve as adjuvants in combination with existing antibiotics to enhance antibacterial activity against drug-resistant Out of 16 prepared SPRLPs, C-PRP was found to significantly potentiate the antibiotics minocycline and rifampin against multidrug- and extensively drug-resistant (MDR/XDR) clinical isolates. This nonhemolytic C-PRP is comprised of the heptapeptide sequence PRPRPRP-NH acylated to dodecanoic acid (C) at the N terminus. The adjuvant potency of C-PRP was apparent by its ability to reduce the MIC of minocycline and rifampin below their interpretative susceptibility breakpoints against MDR/XDR An attempt to optimize C-PRP through peptidomimetic modification was performed by replacing all l- to d-amino acids. C-PRP demonstrated that it was amenable to optimization, since synergism with minocycline and rifampin were retained. Moreover, C-PRP displayed no cytotoxicity against human liver carcinoma HepG2 and human embryonic kidney HEK-293 cell lines. Thus, the SPRLP C-PRP is a lead adjuvant candidate that warrants further optimization. The discovery of agents that are able to resuscitate the activity of existing antibiotics against drug-resistant Gram-negative pathogens, especially , is of great clinical interest.

Citing Articles

New Antimicrobial Strategies to Treat Multi-Drug Resistant Infections Caused by Gram-Negatives in Cystic Fibrosis.

Scoffone V, Barbieri G, Irudal S, Trespidi G, Buroni S Antibiotics (Basel). 2024; 13(1).

PMID: 38247630 PMC: 10812592. DOI: 10.3390/antibiotics13010071.

Synergy by Perturbing the Gram-Negative Outer Membrane: Opening the Door for Gram-Positive Specific Antibiotics.

Wesseling C, Martin N ACS Infect Dis. 2022; 8(9):1731-1757.

PMID: 35946799 PMC: 9469101. DOI: 10.1021/acsinfecdis.2c00193.

Dioctanoyl Ultrashort Tetrabasic β-Peptides Sensitize Multidrug-Resistant Gram-Negative Bacteria to Novobiocin and Rifampicin.

Ramirez D, Berry L, Domalaon R, Li Y, Arthur G, Kumar A Front Microbiol. 2022; 12:803309.

PMID: 35003035 PMC: 8733726. DOI: 10.3389/fmicb.2021.803309.

Effects of Lipidation on a Proline-Rich Antibacterial Peptide.

Armas F, Di Stasi A, Mardirossian M, Romani A, Benincasa M, Scocchi M Int J Mol Sci. 2021; 22(15).

PMID: 34360723 PMC: 8347091. DOI: 10.3390/ijms22157959.

Repurposed Antimicrobial Combination Therapy: Tobramycin-Ciprofloxacin Hybrid Augments Activity of the Anticancer Drug Mitomycin C Against Multidrug-Resistant Gram-Negative Bacteria.

Domalaon R, Ammeter D, Brizuela M, Gorityala B, Zhanel G, Schweizer F Front Microbiol. 2019; 10:1556.

PMID: 31354660 PMC: 6636613. DOI: 10.3389/fmicb.2019.01556.

References

Cassone M, Vogiatzi P, La Montagna R, De Olivier Inacio V, Cudic P, Wade J . Scope and limitations of the designer proline-rich antibacterial peptide dimer, A3-APO, alone or in synergy with conventional antibiotics. Peptides. 2008; 29(11):1878-86. DOI: 10.1016/j.peptides.2008.07.016. View

Yang X, Goswami S, Gorityala B, Domalaon R, Lyu Y, Kumar A . A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria. J Med Chem. 2017; 60(9):3913-3932. DOI: 10.1021/acs.jmedchem.7b00156. View

Mensa B, Howell G, Scott R, DeGrado W . Comparative mechanistic studies of brilacidin, daptomycin, and the antimicrobial peptide LL16. Antimicrob Agents Chemother. 2014; 58(9):5136-45. PMC: 4135847. DOI: 10.1128/AAC.02955-14. View

Silver L . A Gestalt approach to Gram-negative entry. Bioorg Med Chem. 2016; 24(24):6379-6389. DOI: 10.1016/j.bmc.2016.06.044. View

Krizsan A, Volke D, Weinert S, Strater N, Knappe D, Hoffmann R . Insect-derived proline-rich antimicrobial peptides kill bacteria by inhibiting bacterial protein translation at the 70S ribosome. Angew Chem Int Ed Engl. 2014; 53(45):12236-9. DOI: 10.1002/anie.201407145. View

Shlaes D . New β-lactam-β-lactamase inhibitor combinations in clinical development. Ann N Y Acad Sci. 2013; 1277:105-14. DOI: 10.1111/nyas.12010. View

Sivertsen A, Isaksson J, Leiros H, Svenson J, Svendsen J, Brandsdal B . Synthetic cationic antimicrobial peptides bind with their hydrophobic parts to drug site II of human serum albumin. BMC Struct Biol. 2014; 14:4. PMC: 3907362. DOI: 10.1186/1472-6807-14-4. View

Gellatly S, Hancock R . Pseudomonas aeruginosa: new insights into pathogenesis and host defenses. Pathog Dis. 2013; 67(3):159-73. DOI: 10.1111/2049-632X.12033. View

Runti G, Benincasa M, Giuffrida G, Devescovi G, Venturi V, Gennaro R . The Mechanism of Killing by the Proline-Rich Peptide Bac7(1-35) against Clinical Strains of Pseudomonas aeruginosa Differs from That against Other Gram-Negative Bacteria. Antimicrob Agents Chemother. 2017; 61(4). PMC: 5365664. DOI: 10.1128/AAC.01660-16. View

10.

Srinivas N, Jetter P, Ueberbacher B, Werneburg M, Zerbe K, Steinmann J . Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa. Science. 2010; 327(5968):1010-3. DOI: 10.1126/science.1182749. View

11.

Kumar A, Schweizer H . Bacterial resistance to antibiotics: active efflux and reduced uptake. Adv Drug Deliv Rev. 2005; 57(10):1486-513. DOI: 10.1016/j.addr.2005.04.004. View

12.

Hosseininassab Nodoushan S, Yadegari S, Moghim S, Nasr Isfahani B, Fazeli H, Poursina F . Distribution of the Strains of Multidrug-resistant, Extensively Drug-resistant, and Pandrug-resistant Isolates from Burn Patients. Adv Biomed Res. 2017; 6:74. PMC: 5501067. DOI: 10.4103/abr.abr_239_16. View

13.

Qvit N, Rubin S, Urban T, Mochly-Rosen D, Gross E . Peptidomimetic therapeutics: scientific approaches and opportunities. Drug Discov Today. 2016; 22(2):454-462. PMC: 5759319. DOI: 10.1016/j.drudis.2016.11.003. View

14.

Toussaint K, Gallagher J . β-lactam/β-lactamase inhibitor combinations: from then to now. Ann Pharmacother. 2014; 49(1):86-98. DOI: 10.1177/1060028014556652. View

15.

Cerceo E, Deitelzweig S, Sherman B, Amin A . Multidrug-Resistant Gram-Negative Bacterial Infections in the Hospital Setting: Overview, Implications for Clinical Practice, and Emerging Treatment Options. Microb Drug Resist. 2016; 22(5):412-31. DOI: 10.1089/mdr.2015.0220. View

16.

Breidenstein E, de la Fuente-Nunez C, Hancock R . Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol. 2011; 19(8):419-26. DOI: 10.1016/j.tim.2011.04.005. View

17.

Li W, Ma G, Zhou X . Apidaecin-type peptides: biodiversity, structure-function relationships and mode of action. Peptides. 2006; 27(9):2350-9. DOI: 10.1016/j.peptides.2006.03.016. View

18.

Domalaon R, Findlay B, Ogunsina M, Arthur G, Schweizer F . Ultrashort cationic lipopeptides and lipopeptoids: Evaluation and mechanistic insights against epithelial cancer cells. Peptides. 2016; 84:58-67. DOI: 10.1016/j.peptides.2016.07.007. View

19.

Domalaon R, Zhanel G, Schweizer F . Short Antimicrobial Peptides and Peptide Scaffolds as Promising Antibacterial Agents. Curr Top Med Chem. 2015; 16(11):1217-30. DOI: 10.2174/1568026615666150915112459. View

20.

Podda E, Benincasa M, Pacor S, Micali F, Mattiuzzo M, Gennaro R . Dual mode of action of Bac7, a proline-rich antibacterial peptide. Biochim Biophys Acta. 2006; 1760(11):1732-40. DOI: 10.1016/j.bbagen.2006.09.006. View